Zydus Lifesciences Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Zydus Lifesciences Ltd. from all sources in a single place.

Load latest

Zydus Lifesciences Ltd.

09 Apr 2022

1004.50

0.84%

Company Update

Zydus Lifesciences Ltd - 532321 - Format of Initial Disclosure to be made by an entity …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayZydus Lifesciences Ltd 2CINL24230GJ1995PLC025878 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Dhaval N Soni Designation: Company Secretary EmailId: dhavalsoni@zyduslife.com Name of the Chief Financial Officer: Nitin D Parekh Designation: Chief Financial Officer EmailId: nitinparekh@zyduslife.com Date: 09/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Zydus Lifesciences Ltd.

09 Apr 2022

1004.50

0.84%

Cadila Pharma launches world's first novel 3-dose vaccine against rabies

Business Standard

The three-dose vaccine, named as 'ThRabis', is a recombinant nano-particle based G protein vaccine which is prepared using Virus-like Particle technology

Zydus Lifesciences Ltd. is trading above all available SMAs

Cadila Pharma launches three-dose rabies vaccine

Business Line | 08 Apr 2022 1 more

Zydus Lifesciences Ltd.

06 Apr 2022

1004.50

0.84%

Company Update

Zydus Lifesciences Ltd - 532321 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure …

BSE India

Certificate under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended on March 31, 2022

pdf

Zydus Lifesciences Ltd.

05 Apr 2022

1004.50

0.84%

Company Update

Zydus Lifesciences Ltd - 532321 - Statement Of Investor Complaints For The Quarter Ended March 2022

BSE India

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- Dhaval N SoniDesignation :- Company Secretary and Compliance Officer

Zydus Lifesciences Ltd.

05 Apr 2022

1004.50

0.84%

Company Update

Zydus Lifesciences Ltd - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on March 31, 2022

pdf

Zydus Lifesciences Ltd.

01 Apr 2022

1004.50

0.84%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

The Lancet publishes Phase III data of ZyCoV-D

pdf

Zydus Lifesciences Ltd.

25 Mar 2022

1004.50

0.84%

SAST

Zydus Lifesciences Ltd - 532321 - Closure of Trading Window

BSE India

We hereby inform that the trading window shall remain closed from April 1, 2022 till 48 hours after the declaration of audited financial results for the quarter / year ending on March 31, 2022 for the Directors and Designated Persons and their immediate relatives, for trading in the equity shares of the Company.

pdf

Zydus Lifesciences Ltd.

21 Mar 2022

1004.50

0.84%

Company Update

Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Fortress Biotech and Cyprium Therapeutics alongwith Zydus' Sentynl Therapeutics Announce CUTX-101, Copper Histidinate Data to be Presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting

pdf